Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Idarubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | S100A4 | P26447 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idarubicin SCHEMBL16609956 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL12257447 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL15159345 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL13575798 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL18738468 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL3750 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL16606206 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL7029978 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL20541733 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL10061859 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236382-B2 | Method and system for sample preparation | INTEGRATED NANO-TECHNOLOGIES, LLC (US) | 2022-02-01 | — | — | US | disclosed |
| US-10378045-B2 | Method and system for sample preparation | INTEGRATED NANO-TECHNOLOGIES, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-9828405-B2 | Morpholinyl anthracycline derivatives | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-11-28 | — | — | US | disclosed |
| US-9828405-B2 | Morpholinyl anthracycline derivatives | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-11-28 | — | — | US | disclosed |
| US-20170312290-A1 | FUNCTIONALIZED MORPHOLINYL ANTHRACYCLINE DERIVATIVES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-11-02 | — | — | US | disclosed |
| US-20170312290-A1 | FUNCTIONALIZED MORPHOLINYL ANTHRACYCLINE DERIVATIVES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-11-02 | — | — | US | disclosed |
| US-20170292151-A1 | METHOD AND SYSTEM FOR SAMPLE PREPARATION | INTEGRATED NANO-TECHNOLOGIES, LLC (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170292151-A1 | METHOD AND SYSTEM FOR SAMPLE PREPARATION | INTEGRATED NANO-TECHNOLOGIES, LLC (US) | 2017-10-12 | — | — | US | disclosed |
| US-9644200-B2 | Method and system for sample preparation | INTEGRATED NANO-TECHNOLOGIES, LLC (US) | 2017-05-09 | — | — | US | disclosed |
| US-9644200-B2 | Method and system for sample preparation | INTEGRATED NANO-TECHNOLOGIES, LLC (US) | 2017-05-09 | — | — | US | disclosed |
| US-8663918-B2 | Method and system for sample preparation | INTEGRATED NANO-TECHNOLOGIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20140024822-A1 | METHOD AND SYSTEM FOR SAMPLE PREPARATION | CONNOLLY, DENNIS MICHAEL | 2014-01-23 | — | — | US | disclosed |
| US-20140024822-A1 | METHOD AND SYSTEM FOR SAMPLE PREPARATION | CONNOLLY, DENNIS MICHAEL | 2014-01-23 | — | — | US | disclosed |
| US-20100041034-A1 | METHOD FOR MANIPULATING SAMPLES WITH MAGNETIC NUCLEATION NANOPARTICLES | INTEGRATED NANO-TECHNOLOGIES, LLC | 2010-02-18 | — | — | US | disclosed |
| US-20100041034-A1 | METHOD FOR MANIPULATING SAMPLES WITH MAGNETIC NUCLEATION NANOPARTICLES | INTEGRATED NANO-TECHNOLOGIES, LLC | 2010-02-18 | — | — | US | disclosed |
| US-20090270593-A1 | NUCLEIC ACID BINDING SUBSTANCE CONTAINING CATALYTIC NUCLEATION NANOPARTICLES | INTEGRATED NANO-TECHNOLOGIES, LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090270593-A1 | NUCLEIC ACID BINDING SUBSTANCE CONTAINING CATALYTIC NUCLEATION NANOPARTICLES | INTEGRATED NANO-TECHNOLOGIES, LLC | 2009-10-29 | — | — | US | disclosed |
| US-7531162-B2 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531162-B2 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
| US-7442385-B2 | Chemoembolisation | BIOCOMPATIBLES UK LIMITED (GB) | 2008-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312290-A1 | FUNCTIONALIZED MORPHOLINYL ANTHRACYCLINE DERIVATIVES | CCNY, BCR, CCNB3 | TOP2A 562/4885MEN1 768/4885THRB 1061/4885 |
| US-20090270593-A1 | NUCLEIC ACID BINDING SUBSTANCE CONTAINING CATALYTIC NUCLEATION NANOPARTICLES | RNGTT, CNBP, SNRPE | TOP2A 394/4885MEN1 3665/4885THRB 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.